Momenta Pharmaceuticals Announces U.S. Court of Appeals Decision to Remand Enoxaparin Case Back to District Court

CAMBRIDGE, Mass., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. MNTA today announced that the United States Court of Appeals for the Federal Circuit (CAFC) has vacated the Massachusetts district court's summary judgment in favor of Amphastar to the extent it was based on the scope of the "safe harbor" under 271(e)(1). In reaching this decision, the CAFC found that Amphastar's alleged use of the Company's patent is not eligible for the 35 USC §271(e)(1) safe harbor. The CAFC remanded this portion of the case to the Massachusetts district court for further proceedings.

The CAFC separately affirmed the Massachusetts district court's summary judgment to the extent it relates to infringement by Amphastar, Actavis and Teva under 35 USC § 271(g). 

"We are pleased with the CAFC's decision to remand our case against Amphastar back to the District Court allowing us to continue to pursue our enoxaparin patent infringement litigation," said Craig Wheeler, President and Chief Executive Officer of Momenta.

About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural and functional analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for oncology and autoimmune indications.

To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release. The company's logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.

Forward Looking Statements
Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, including statements relating to its beliefs and intentions related to the outcome of litigation with Amphastar Pharmaceuticals and Teva Pharmaceuticals, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "hope," "target," "project," "goals," "potential," "predict," "might," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors referred to in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2015 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Momenta from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. Momenta is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.